Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Chantal Mathieu

Showing results (311-320 of 626) with videos related to

Pageof 63
Sort By:
Diabetes Technology & Therapeutics|June 1, 2006
Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) modelElvira Mueller, Stefanie Maxion-Bergemann, Dmitry Gultyaev, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 7, 2010
The vitamin D analog, TX527, promotes a human CD4+CD25highCD127low regulatory T cell profile and induces a migratory signature specific for homing to sites of inflammationFemke Baeke, Hannelie Korf, Lut Overbergh, et al.
Diabetes Care|April 20, 2021
A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100Ildiko Lingvay, John B Buse, Edward Franek, et al.
Diabetes Technology & Therapeutics|November 28, 2025
A Phase 2 (2a) Randomized Trial of Iscalimab in Adolescents and Young Adults with New-Onset Type 1 DiabetesChantal Mathieu, Michelle Quinlan, Kristina Wagner, et al.
Diabetes|March 29, 2006
Survival benefits of intensive insulin therapy in critical illness: impact of maintaining normoglycemia versus glycemia-independent actions of insulinBjörn Ellger, Yves Debaveye, Ilse Vanhorebeek, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 21, 2012
Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE StudyStephan Matthaei, Matthew Reaney, Chantal Mathieu, et al.
Diabetologia|September 13, 2024
Metabolic health in people living with type 1 diabetes in Belgium: a repeated cross-sectional studyAstrid Lavens, Christophe De Block, Philippe Oriot, et al.
Diabetes, Obesity & Metabolism|August 31, 2021
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trialsThomas F Dejgaard, Bernt J von Scholten, Erik Christiansen, et al.
Diabetes, Obesity & Metabolism|April 21, 2020
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trialChantal Mathieu, Gottfried Rudofsky, Moshe Phillip, et al.
Transplantation|May 24, 2008
Late CD8+ T cell-dependent xenoantibody production in innate tolerant nude rats after hamster islet grafting but not after hamster heart graftingTimothy Devos, Li Shengqiao, Conny Gysemans, et al.
Pageof 63

Showing results (311-320 of 626) with videos related to

Sort By:
Pageof 63
Diabetes Technology & Therapeutics|June 1, 2006
Development and validation of the Economic Assessment of Glycemic Control and Long-Term Effects of diabetes (EAGLE) modelElvira Mueller, Stefanie Maxion-Bergemann, Dmitry Gultyaev, et al.
Journal of Immunology (Baltimore, Md. : 1950)|December 7, 2010
The vitamin D analog, TX527, promotes a human CD4+CD25highCD127low regulatory T cell profile and induces a migratory signature specific for homing to sites of inflammationFemke Baeke, Hannelie Korf, Lut Overbergh, et al.
Diabetes Care|April 20, 2021
A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100Ildiko Lingvay, John B Buse, Edward Franek, et al.
Diabetes Technology & Therapeutics|November 28, 2025
A Phase 2 (2a) Randomized Trial of Iscalimab in Adolescents and Young Adults with New-Onset Type 1 DiabetesChantal Mathieu, Michelle Quinlan, Kristina Wagner, et al.
Diabetes|March 29, 2006
Survival benefits of intensive insulin therapy in critical illness: impact of maintaining normoglycemia versus glycemia-independent actions of insulinBjörn Ellger, Yves Debaveye, Ilse Vanhorebeek, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders|June 21, 2012
Patients with Type 2 Diabetes Initiating Exenatide Twice Daily or Insulin in Clinical Practice: CHOICE StudyStephan Matthaei, Matthew Reaney, Chantal Mathieu, et al.
Diabetologia|September 13, 2024
Metabolic health in people living with type 1 diabetes in Belgium: a repeated cross-sectional studyAstrid Lavens, Christophe De Block, Philippe Oriot, et al.
Diabetes, Obesity & Metabolism|August 31, 2021
Efficacy and safety of liraglutide in type 1 diabetes by baseline characteristics in the ADJUNCT ONE and ADJUNCT TWO randomized controlled trialsThomas F Dejgaard, Bernt J von Scholten, Erik Christiansen, et al.
Diabetes, Obesity & Metabolism|April 21, 2020
Long-term efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (the DEPICT-2 study): 52-week results from a randomized controlled trialChantal Mathieu, Gottfried Rudofsky, Moshe Phillip, et al.
Transplantation|May 24, 2008
Late CD8+ T cell-dependent xenoantibody production in innate tolerant nude rats after hamster islet grafting but not after hamster heart graftingTimothy Devos, Li Shengqiao, Conny Gysemans, et al.
Pageof 63